Skip to main content
. 2023 Feb 17;9:67. doi: 10.1038/s41420-023-01366-5

Fig. 4. Recombinant IL-35 supplement suppresses severe colitis symptoms in a DSS-induced colitis mouse model.

Fig. 4

A Wildtype (WT) mice were pre-treated with recombinant IL-35 or IgG isotype intravenously 48 h before 2.5% dextran sulfate sodium (DSS) administration. B Body weight was calculated (n = 4 per group). C Disease activity index (DAI) was calculated (n = 4 per group). D Representative colon sections are shown for each group (left panel). Length of the colon is shown on the bar graph (right panel) (n = 4 per group). E Survival analysis of each group was calculated (n = 10 per group). F Representative colon sections stained with hematoxylin and eosin (upper panels) and periodic acid-Schiff (lower panels) are shown for each group. Images are shown at ×100 magnification. Histological sections were blindly scored on a scale of 0–4 to generate a histological score and individual mouse scores are shown with each data point representing a single mouse (n = 4 per group). B, C Two-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test. D, F Two-tailed unpaired Student’s t-test. E Log-rank (Mantel–Cox) test. Data are shown as mean ± standard error of the mean (SEM) and are representative of at least three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).